Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in four upcoming conferences in August and September 2025.
The conferences include the 36th International Epilepsy Congress in Lisbon (Aug 30-Sep 3), Cantor Global Healthcare Conference (Sep 5), H.C. Wainwright Global Investment Conference (Sep 9), and Baird Global Healthcare Conference (Sep 10). A live webcast will be available for the Cantor event through the company's investor relations website, with replay accessible for 60 days.
Bright Minds Biosciences (NASDAQ: DRUG), azienda che sviluppa agonisti selettivi 5-HT2 per il trattamento dell'epilessia resistente ai farmaci, della depressione e di altri disturbi del SNC, ha annunciato la sua partecipazione a quattro conferenze previste per agosto e settembre 2025.
Gli eventi comprendono il 36° Congresso Internazionale sull'Epilessia a Lisbona (30 ago-3 set), il Cantor Global Healthcare Conference (5 set), l'H.C. Wainwright Global Investment Conference (9 set) e il Baird Global Healthcare Conference (10 set). Per l'evento Cantor sarà disponibile una webcast in diretta sul sito degli investor relations della società, con la registrazione accessibile in replay per 60 giorni.
Bright Minds Biosciences (NASDAQ: DRUG), empresa que desarrolla agonistas selectivos de 5-HT2 para el tratamiento de la epilepsia resistente a medicamentos, la depresión y trastornos del SNC, ha anunciado su participación en cuatro conferencias programadas para agosto y septiembre de 2025.
Los eventos incluyen el 36.º Congreso Internacional de Epilepsia en Lisboa (30 ago-3 sep), la Cantor Global Healthcare Conference (5 sep), la H.C. Wainwright Global Investment Conference (9 sep) y la Baird Global Healthcare Conference (10 sep). Para el evento de Cantor habrá una retransmisión en directo disponible en el sitio web de relaciones con inversores de la compañía, con la grabación accesible en replay durante 60 días.
Bright Minds Biosciences (NASDAQ: DRUG)는 약물 내성 간질, 우울증 및 중추신경계(CNS) 질환 치료를 위해 선택적 5-HT2 작용제를 개발하는 회사로, 2025년 8월과 9월에 열리는 네 건의 학회에 참가한다고 발표했습니다.
참석 예정인 행사는 제36회 국제 간질 학회(리스본, 8월30일–9월3일), Cantor Global Healthcare Conference(9월5일), H.C. Wainwright Global Investment Conference(9월9일), Baird Global Healthcare Conference(9월10일)입니다. Cantor 행사에 대해서는 회사 투자자 관계 웹사이트를 통해 실시간 웹캐스트가 제공되며, 재생은 60일 동안 이용할 수 있습니다.
Bright Minds Biosciences (NASDAQ: DRUG), entreprise développant des agonistes sélectifs 5‑HT2 pour le traitement de l'épilepsie résistante aux médicaments, de la dépression et des troubles du SNC, a annoncé sa participation à quatre conférences prévues en août et septembre 2025.
Les événements incluent le 36e Congrès international sur l'épilepsie à Lisbonne (30 août–3 sept), la Cantor Global Healthcare Conference (5 sept), la H.C. Wainwright Global Investment Conference (9 sept) et la Baird Global Healthcare Conference (10 sept). Un webcast en direct sera disponible pour l'événement Cantor sur le site des relations investisseurs de la société, avec la rediffusion accessible pendant 60 jours.
Bright Minds Biosciences (NASDAQ: DRUG), ein Unternehmen, das selektive 5‑HT2‑Agonisten zur Behandlung von medikamentenresistenter Epilepsie, Depression und ZNS‑Erkrankungen entwickelt, hat seine Teilnahme an vier Konferenzen im August und September 2025 angekündigt.
Zu den Veranstaltungen zählen der 36. Internationale Epilepsiekongress in Lissabon (30. Aug–3. Sep), die Cantor Global Healthcare Conference (5. Sep), die H.C. Wainwright Global Investment Conference (9. Sep) und die Baird Global Healthcare Conference (10. Sep). Für das Cantor‑Event wird ein Live‑Webcast auf der Investor‑Relations‑Website des Unternehmens angeboten, die Aufzeichnung ist 60 Tage lang abrufbar.
- None.
- None.
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:
| EVENT: | 36th International Epilepsy Congress, Lisboa Congress Centre, Lisbon, Portugal |
| DATE: | August 30 – September 3, 2025 |
| EVENT: | Cantor Global Healthcare Conference 2025 |
| DATE: | Friday, September 5, 2025 |
| TIME: | 9:45am ET |
| WEBCAST: | https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=37737154 |
| EVENT: | H.C. Wainwright 27th Annual Global Investment Conference |
| DATE: | Tuesday, September 9, 2025 |
| TIME: | 3:00pm ET |
| WEBCAST: | There is no webcast for this event |
| EVENT: | Baird 2025 Global Healthcare Conference |
| DATE: | Wednesday, September 10, 2025 |
| TIME: | 9:05am ET |
| WEBCAST: | There is no webcast for this event |
The live and archived webcast for the Cantor event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact Information
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
FAQ
When is Bright Minds Biosciences (NASDAQ: DRUG) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Bright Minds Biosciences' presentation at the Cantor Conference?
What therapeutic areas is Bright Minds Biosciences (DRUG) focusing on?
Which conferences will Bright Minds Biosciences attend in September 2025?
